肿瘤细胞治疗研究
FRONTIER PAPERS
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T-Treated T-cell Lymphoid Malignancies.
综合而言，这些发现表明，在 CD7 CAR-T 细胞疗法的选择压力下，克隆异质性和表观遗传可塑性共同驱动 T 细胞淋巴系统恶性肿瘤的抗原阴性复发。
Correction: CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.
Efficacy, Safety, and Kinetics of Naturally Selected Anti-CD7 CAR-T Cell Therapy in T-ALL/LBL With CNS Leukemia.
TA-TMA occurring after sequential CD7 CAR-T cell therapy and allogeneic hematopoietic stem cell transplantation: a case report.
目前，CAR-T细胞治疗桥接异基因造血干细胞移植（allo-HSCT）已成为难治/复发性血液系统恶性肿瘤的关键治疗策略。
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.
在3个月内，89%的接受治疗患者达到了部分缓解或更好的最佳总体缓解。
Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.
本研究利用单细胞测序技术，探究T细胞急性淋巴细胞白血病患者在接受5CAR或7CAR治疗后的免疫失调情况。
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
CD7在约30%的AML病例中表达，是一个有前景的靶点。
Engineering fratricide-resistant CCR4/CD7 CAR T cells with enhanced safety and persistence for T cell malignancies.
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia.
约 30% 的急性髓系白血病（AML）患者的原始粒细胞表达 CD7。
MEMBER ACCOUNT
登录成功会直接打开下一页。
